Dr. Dolezal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Palo Alto, CA 94304Phone+1 650-723-4000
Summary
- Breast cancer specialist, Cancer survivorship/supportive care director, Clinical trials advocate, passionate about living strong and committed to teaching people about healthy living both during and after treatments. Veteran triathlete and iron(wo)man along with Tour of Hope across USA bicycle rider. Speaker/consultant for several companies involved in molecular platforms and targeted personalized cancer treatment options.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 1999 - 2002
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1999
Certifications & Licensure
CA State Medical License 2001 - 2024- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
- Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. Start of enrollment: 2015 Jun 09
Publications & Presentations
PubMed
- 28 citationsClonal VDJ recombination of the immunoglobulin heavy chain gene by PCR in classical Hodgkin's disease.Onsi W. Kamel, Pearl Chang, Frank J. Hsu, Milana V. Dolezal, Roger A. Warnke
American Journal of Clinical Pathology. 1995-10-01 - 34 citationsFertility preservation before breast cancer treatment appears unlikely to affect disease-free survival at a median follow-up of 43 months after fertility-preservation ...Joseph M. Letourneau, Kaitlyn Wald, Nikita Sinha, Flor Juarez-Hernandez, E. Harris
Cancer. 2020-02-01 - 9 citationsConcomitant tamoxifen or letrozole for optimal oocyte yield during fertility preservation for breast cancer: the TAmoxifen or Letrozole in Estrogen Sensitive tumors (T...Joseph M. Letourneau, Flor Juarez-Hernandez, Kaitlyn Wald, Salustiano Ribeiro, Ange Wang
Journal of Assisted Reproduction and Genetics. 2021-07-26
Press Mentions
Considering Novel Therapy for HER2+ Metastatic Breast CancerMay 20th, 2022- Nearly Half of U.S. Cancer Deaths Are Linked to Controllable RisksJuly 18th, 2024
External Links
- Stanford https://stanfordhealthcare.org/doctors/d/milana-dolezal.html
- http://cancersurvivorshipsexualhealth.eventbrite.com/http://cancersurvivorshipsexualhealth.eventbrite.com/
- http://cancersurvivorshipsexualhealth.eventbrite.com/http://cancersurvivorshipsexualhealth.eventbrite.com/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
